The FDA has approved Donanemab, marketed as Kisunla, as a new treatment for individuals in the early stages of Alzheimer’s disease. Manufactured by Eli Lilly, Kisunla has shown to slow cognitive decline in clinical trials. It targets amyloid plaque buildup in the brain, reducing the risk of progressing to the next stage of the disease. The drug involves a limited-duration treatment regimen with monthly infusions that can be stopped once all amyloid plaques are cleared. Though there are potential side effects, experts are optimistic about the impact of Kisunla on Alzheimer’s treatment. The price of the treatment is $695.65 per vial, with a six-month treatment costing $12,522 and a 12-month treatment costing $32,000.
Source link
What Is Kisunla? Know All About New FDA-Approved Drug For Alzheimer’s Disease
